Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALV NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$26.72+0.0%$18.89$9.83▼$26.85$1.37B-0.125.76 million shs6.49 million shsXENEXenon Pharmaceuticals$58.66+1.6%$54.41$28.19▼$63.95$5.58B0.65921,889 shs724,088 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals+0.04%+0.19%+32.34%+85.56%+114.03%XENEXenon Pharmaceuticals+1.63%+5.21%+3.19%+45.22%+66.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$26.72+0.0%$18.89$9.83▼$26.85$1.37B-0.125.76 million shs6.49 million shsXENEXenon Pharmaceuticals$58.66+1.6%$54.41$28.19▼$63.95$5.58B0.65921,889 shs724,088 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals+0.04%+0.19%+32.34%+85.56%+114.03%XENEXenon Pharmaceuticals+1.63%+5.21%+3.19%+45.22%+66.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALVKalVista Pharmaceuticals 2.22Hold$30.6014.52% UpsideXENEXenon Pharmaceuticals 3.00Buy$73.1324.67% UpsideCurrent Analyst Ratings BreakdownLatest XENE and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026KALVKalVista Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$37.00 ➝ $27.004/30/2026KALVKalVista Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2026KALVKalVista Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/21/2026KALVKalVista Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026KALVKalVista Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $42.003/26/2026KALVKalVista Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$29.00 ➝ $28.003/25/2026KALVKalVista Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $36.003/16/2026XENEXenon Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$64.00 ➝ $63.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALVKalVista Pharmaceuticals$49.08M27.89N/AN/A$2.71 per share9.86XENEXenon Pharmaceuticals$7.50M755.80N/AN/A$7.53 per share7.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALVKalVista Pharmaceuticals-$109.52M-$3.95N/A45.29N/AN/A-214.88%-81.87%5/7/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.36N/AN/AN/AN/A-55.81%-52.04%5/7/2026 (Estimated)Latest XENE and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026N/AKALVKalVista Pharmaceuticals-$0.3763-$0.92-$0.5438N/A$39.14 million$13.69 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17N/AN/AN/A$1.36 millionN/A2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALVKalVista Pharmaceuticals8.187.227.21XENEXenon PharmaceuticalsN/A13.4113.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALVKalVista PharmaceuticalsN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipKALVKalVista Pharmaceuticals4.30%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALVKalVista Pharmaceuticals10051.22 million49.02 millionOptionableXENEXenon Pharmaceuticals21096.64 million92.71 millionOptionableXENE and KALV HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6 at 3:15 AM | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on MondayMay 4 at 11:48 AM | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comJennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comXenon to Report Q1 2026 Financial Results on May 7, 2026April 30, 2026 | globenewswire.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)April 30, 2026 | marketbeat.comXenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceApril 26, 2026 | marketbeat.comPeregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENEApril 24, 2026 | marketbeat.comXenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereApril 23, 2026 | insidermonkey.comXenon's Phase 3 Supports A 'Buy' Despite Its PremiumApril 22, 2026 | seekingalpha.comXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal ...April 19, 2026 | caledonianrecord.comCXenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026April 19, 2026 | quiverquant.comQXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingApril 19, 2026 | globenewswire.comXenon Pharmaceuticals Inc.April 19, 2026 | edition.cnn.comXenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)April 16, 2026 | marketbeat.comXenon to Present at Upcoming Investor ConferencesApril 15, 2026 | globenewswire.comXenon Expands 2025 Inducement Equity Incentive PlanApril 13, 2026 | tipranks.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by BrokeragesApril 11, 2026 | marketbeat.comXenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual MeetingApril 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXENE and KALV Company DescriptionsKalVista Pharmaceuticals NASDAQ:KALV$26.72 +0.01 (+0.04%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$26.62 -0.10 (-0.37%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$58.66 +0.95 (+1.64%) Closing price 05/6/2026 03:59 PM EasternExtended Trading$58.62 -0.03 (-0.06%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
